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ABSTRACT:  
Background: Authors have continued clinical practice and research of Calorie 
Restriction (CR), Low Carbohydrate Diet (LCD) and Morbus (M) value for long.  
Subjects and Methods: Subjects were 32 type 2 diabetes mellitus (T2DM) with more 
than 10 μU/mL of fasting immunoreacitve insulin (IRI). Methods included fundamental 
tests such as glucose, IRI, homeostasis model assessment (HOMA)-R, HOMA-β, and so 
on.  
Results: Obtained data were as follows: average age 57.6 ± 12.8 years old, average 
HbA1c 7.6%. Median values are: average glucose 166 mg/dL, M value 46.6, fasting 
glucose 140 mg/dL, fasting IRI 12.4 μU/mL, HOMA-R 4.5, HOMA-β 60.3. M value 
showed significant correlation with HOMA-R and HOMA-β (p<0.01). M value showed 
significant correlations with HbA1c, average glucose, HOMA-R, HOMA-β (p<0.01). For 
the responses of glucose and IRI for 70g of carbohydrate, Delta Ratio of insulinogenic 
index (IGI) and Area Under the Curves (AUC) Ratio of IGI were studied. Significant 
correlation existed between HOMA-β and AUC Ratio of IGI (p<0.01). 
Discussion and Conclusion: These results suggested the relationship among average 
glucose, HbA1c, M value, HOMA-R, HOMA-β, IGI, Delta and AUC Ratio of IGI, and so on. 
These findings would become fundamental and reference data for the future study in 
this field. 
 
Keywords: Morbus value (M value), Type 2 diabetes mellitus (T2DM), Calorie 
Restriction (CR), Homeostasis model assessment (HOMA), Insulinogenic Index (IGI), 
Area Under the Curve (AUC). 
 
1 Introduction 
The patients with diabetes has been increased in 
developed countries and developing countries [1]. In 
regard to clinical diabetic management, rather paradigm 
changes have been observed. American College of 
Physicians (ACP) proposed the change in standard value 
about HbA1c [2]. Furthermore, American Diabetes 
Association (ADA) presented the comments about the 
goals and treatment for diabetes [3].  
In succession, the Prospective Urban Rural 
Epidemiology (PURE) studies were reported as large-scale 
epidemiological studies. They have covered about 140 
thousands subjects in 600 communities from 18 countries 
[4]. Out of these studies, it was found that higher 
carbohydrate intake has an increased risk of total 
mortality (HR 1.28), and that reducing intake of 
carbohydrate would be recommended [5]. Moreover, 
standard guideline was presented from International 
Diabetes Federation (IDF) [6].  
As to the nutritional therapy for diabetes, there 
have been various discussion about Low Carbohydrate 
Diet (LCD) and Calorie Restriction (CR) [7-9]. In Japan, 
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authors and colleagues have begun LCD, and treated lots of 
cases with clinical efficacy [10]. We have investigated 
related research concerning CR and/or LCD formula 
meals, elevated ketone bodies, Morbus (M) value, lipid 
metabolism, renal function [11-13]. In addition, three 
types of LCD meal were proposed, which are super, 
standard and petite LCDs [14]. Furthermore, we continued 
and developed LCD broadly in Japan by seminars, books 
and medical papers through Japanese LCD promotion 
association [15].  
Along our clinical investigation concerning LCD 
and CR, we proposed new index that is simple and useful 
method. Similar to 75g oral glucose tolerance test 
(75gOGTT) and insulinogenic index (IGI) to carbohydrate 
75g, we have tried to take advantage of breakfast of CR 
including Carbohydrate 70g (Carbo70). Corresponding to 
IGI-75gOGTT, IGI-Carbo70 was proposed and its clinical 
usefulness was investigated [16]. Along to this research 
direction, we developed the research in this study. 
 
2 Subjects and Methods 
We enrolled 32 patients with Type 2 Diabetes 
Mellitus (T2DM) in this study. As the background of the 
subjects, they were diagnosed as T2DM and/or in the 
diabetic state before the diagnosis of T2DM. For further 
evaluation and treatment, they were admitted to the 
hospital. On admission, they were not provided medicine 
for influencing blood glucose. Moreover, subjects were 
selected who showed fasting immunoreactive insulin (IRI) 
more than 10μU/mL. Subjects with IRI level 10μU/mL and 
less than 10μU/mL were excluded in this study.  
As regard to the research methods, we have taken 
our formula protocol of diabetic evaluation. We decided to 
follow some certain criteria about this investigation. 
a) Subjects were admitted to the hospital for 2 
weeks. On the morning of day 2, basal data were obtained 
from the blood samples after overnight fasting. They 
include several biomarkers such as complete blood count, 
liver, renal function, lipid metabolism and so on. For 
diabetic aspect, HbA1c, glucose, IRI, C-peptide, M value, 
homeostasis model assessment of insulin resistance 
homeostasis model assessment of insulin resistance 
(HOMA-R) and homeostasis model assessment of β cell 
function (HOMA-β) were calculated.  
b) For our diabetic research protocol program, CR 
and LCD were provided. Subjects have CR on day 1 and 2 
and LCD from day 3 to 14. On the morning of day 2, 
subjects were provided CR breakfast with carbohydrate 
70g. This breakfast has the content that PFC ratio was 
protein 15%, fat 25%, carbohydrate 60%, with 1400 
kcal/day. It is along to the standard guideline in 
nutritional therapy which was proposed by Japan Diabetes 
Society (JDS) [17].  
c) Similar to 75 gOGTT, 70g of carbohydrate in CR 
breakfast was given to the subjects. Blood samples were 
drawn for blood glucose and IRI on 0 and 30 min. During 
half an hour after the breakfast, subjects were to keep still 
on sitting position. From the data of glucose and IRI, the 
ratio of IRI response against glucose response was 
calculated.  
  d) Daily profile of blood glucose was investigated 
on day 2. The clock time was 08, 10, 12, 14, 17, 19, 22h, 7 
times a day. Average blood glucose value and Morbus (M) 
value were calculated. 
  e) In our usual research protocol, CR meal is 
provided on day 1 and 2, and super LCD is provided from 
day 3 to 14. We have three types of LCD, which are super, 
standard and petite LCDs, in which the ratio of 
carbohydrate is 12%, 26%, 40%, respectively. In this 
study, we utilized the data from only day 2, and do not use 
data from day 3 to 14 or data from LCD.  
 
2.1 Ratio of insulin/glucose response 
  Insulinogenic Index (IGI) has been known from 
the data of glucose and IRI on 0 and 30 min in 75gOGTT. 
Similar to this calculation, we have tried two kinds of 
calculating ratios for 70g of carbohydrate meal. As the 
formula of IGI shows delta (increment) of insulin (30min – 
0 min) / delta (increment) of blood glucose (30min – 
0min). In this report, this ratio is called as ‘Delta Ratio of 
IGI for Carbo70’. 
  Another estimating method is from the usage of 
Area Under the Curves (AUC) of the glucose and IRI for 
70g of carbohydrate. The ratio between IRI and glucose 
would be called as ‘ AUC Ratio of IGI for Carbo70’. 
  From described above, two ratios are defined as 
follows: Delta Ratio of IGI for Carbo70 is calculated as (IRI 
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at 30min – IRI at 0min)(μU/mL) / (Glucose at 30min – 
Glucose at 0min)(mg/dL).  
Similarly, AUC Ratio of IGI for Carbo70 is 
calculated as (AUC of IRI for 0-30min) (μU/mL x h)/ (AUC 
of glucose for 0-30min)(mg/dL x h).  
 
2.2 Daily profile of blood glucose 
  For blood glucose variability, daily profile of 
blood glucose in a day was studied on day 2. Blood 
samples were drawn and measured 7 times a day. The 
time were 08, 13, 12, 14, 17, 19, 22h.From these data, we 
calculated average blood glucose a day and also the level 
of M value according to the certain mathematical equation 
[18,19].  
 
2.3 Morbus value  
M value is the useful biomarker for glucose 
variability. Its characteristic benefit is expressing two 
aspects in clinical practice. One is the average blood 
glucose value obtained from 7 times a day, and another is 
mean amplitude of glycemic excursions (MAGE) [18-20]. 
Consequently, it is useful for research because of 
expressing simply one numerical value.  
By mathematical equation, M value can be 
calculated easily as the logarithmic transformation. The 
significance of M value would be the expression of the 
glucose deviation from the ideal glucose variability [19-
21]. 
The following steps are the calculation of the M 
value. At first, M = MBS + MW : M value is the total of MBS 
and MW. In addition, MW is (maximum blood glucose − 
minimum glucose)/20. Furthermore, MBS expresses the 
mean of MBSBS. Summarized these equations, MBSBS has 
been the individual M-value for each blood glucose, which 
is calculated as (absolute value of [10 × log (blood glucose 
level/120)])3 [19-21]. 
As to the interpretation of the M value, the 
following would be the standard judgment. Generally 
speaking the value less than 180 is normal range, from 180 
to 320 is borderline, and more than 320 is abnormal. 
 
 
2.4 Statistical analysis 
Regarding this study, the data were shown by the 
mean and standard deviation. In addition, some data were 
also shown as the median and quartile of 25% / 75%. 
When investigating the correlation with biomarkers, we 
used Spearman test for the judgment of the correlation 
coefficients. In these analyses, the computerized standard 
statistical tool for analytical evaluation was utilized [22]. 
 
2.5 Ethical Considerations 
Current study was conducted in compliance with 
the ethical principles based upon the Declaration of 
Helsinki. In addition, other commentary was done in the 
Ethical Guidelines for Medical Research in Humans and in 
accordance with the Good Clinical Practice (GCP), 
associated with the consideration to the protection of 
subjects’ human rights. Furthermore, there was adequate 
guideline for application, which was the “Ethical 
Guidelines for Epidemiology Research” by the Ministry of 
Education, Culture, Sports, Science and Technology and 
the Ministry of Health, Labor and Welfare. 
Author and colleagues have our ethical committee 
in the hospital. Several members including physician, 
nurse, pharmacist and other experts for the legal specialty 
attended and discussed. Regarding this study, we 
confirmed that current study was valid and agreed. 
Moreover, we have taken the informed consents and 
written paper agreements from the subjects. Current 
investigation has been registered for recognized study by 
National University Hospital Council of Japan (ID: 
#R000031211). 
 
3 Results 
3.1 Fundamental data 
Enrolled subjects (n=32) revealed the basal data 
(Table 1). Average age was 57.6 ± 12.8 years old with 58 
years old in median. Average HbA1c was 7.6%, while 
median value of HbA1c was 7.2%. Median value of average 
blood glucose and M value was 166 mg/dL and 46.6, 
respectively.  
From the data of fasting glucose and IRI, HOMA-R 
and HOMA-β was calculated (Table 2). The median value 
of HOMA-R and HOMA-β was 4.5 and 60.3, respectively. 
 
Table 1 Subjects and fundamental data 
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Table 2 Estimation for HOMA- R and HOMA - β 
  
Table 3 Delta Ratio and AUC Ratio for Carbo 70 
 
3.2 IGI study for carbohydrate 70g 
The responses of glucose and IRI for carbohydrate 
70g were shown in Table 3. Median values of glucose for 0 
vs 30min and IRI for 0 vs 30 min were 140mg/dL vs 186 
mg/dL, 12.4μU/mL vs 30.6μU/mL, respectively. According 
to the 2 kinds of calculation of insulinogenic index (IGI), 
the median values were 0.45 in Delta Ratio and 13.6 in 
AUC Ratio, respectively. 
 
3.3 Correlation of M value to glucose  
Correlation of M value with HbA1c or average 
blood glucose were shown in Figure 1. There was 
significant correlation between M value and HbA1c 
(p<0.01) (Fig.1a). There was significant correlation 
between M value and average blood glucose (p<0.01) 
(Fig.1b). 
 
 
 
 
 
Figure 1(a): Correlation of M value with HbA1c. There 
was significant correlation between M value and HbA1c 
(p<0.01). 
 
 
 
 
  Mean  SD Median [25%-75%] 
Subjects Number (M/F) 
Age (years old) 
32 (12/20) 32 (12/20) 
57.6 12.8 58 [51 – 66] 
Glucose Profile HbA1c (%) 
Average Glucose (mg/dL) M value 
7.6  2.0  7.2 [6.1 – 8.2] 
171  55.1  166 [121 – 197] 
100  134 46.6 [9.7 – 129]  
Lipid metabolism  Triglyceride (mg/dL) 
HDl-C (mg/dL) 
LDL- C (mg/dL)  
169  112 140 [113 – 197] 
51.5  10.9 51.0 [43.8 – 57.5] 
126  31.4  123 [104 – 144]  
  Mean  SD Median [25% - 75%] 
HOMA calculation Fasting glucose (mg/dL) 146   36.5 140 [119 – 159]  
Fasting [R] (µU/mL) 13.9   3.8 12.4 [11.6 – 16.0] 
HOMA – R 4.8   1.6 4.5 [3.8 – 5.2] 
HOMA - β 77.5   43.6 60.3 [45.2 – 93.8] 
  Mean  SD Median [25% - 75%] 
 
Insulinogenic Index  
Glucose (0 min) (mg/dL) 146   36.5 140 [119 – 159]  
Glucose (30 min)  (mg/dL)  193   46.2 186 [172 – 220] 
[R] (0 min) (µU/mL) 13.9   3.8 12.4 [11.6 – 16.0] 
[R] (30min) (µU/mL) 37.7   21.2 30.6 [24.4 – 51.1] 
[R] Calculation Delta Ratio 0.76  0.98 0.45 [0.19 – 0.90] 
AUC Ratio  16.9  10.6 13.6 [9.7 – 21.9] 
y = 0.6801e0.5417x 
R² = 0.4856 
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Figure 1(b): Correlation of M value with average blood 
glucose. There was significant correlation between M 
value and average blood glucose (p<0.01). 
 
3.4 Correlation of M value with HOMA 
Correlations of M value with 2 kinds of HOMA 
were shown in Figure 2. There was significant correlation 
between M value and HOMA-R (p<0.01) (Fig.2a). There 
was significant correlation between M value and HOMA-β 
(p<0.01) (Fig.2b).  
 
3.5 Correlation of HOMA and IGI 
Correlations of HOMA-β with Delta or AUC Ratio 
of IGI were shown in Fig.3. There was significant 
correlation between HOMA-β and Delta Ratio of IGI 
(p<0.01) (Fig.3a). In addition, There was significant 
correlation between HOMA-β and AUC Ratio of IGI 
(p<0.01) (Fig.3b). 
Figure 2(a): Correlation of M value with HOMA. There 
was significant correlation between M value and HOMA-R 
(p<0.01). 
 
Figure 2(b): Correlation of M value with HOMA. There 
was significant correlation between M value and HOMA-β 
(p<0.01).  
Figure 3 (a): Correlation of HOMA-β with Delta. There 
was not significant correlation between HOMA-β and Delta 
Ratio of IGI.  
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Figure 3(b): Correlation of HOMA-β with AUC Ratio of IGI. 
There was significant correlation between HOMA-β and 
AUC Ratio of IGI (p<0.01). 
 
 
 
4 Discussion 
Authors and colleagues have continued clinical 
research concerning LCD, CR and Morbus (M) value in 
various papers. Among them, one of the characteristic 
point for research would be the utilization of M value [18-
20].  
In the clinical practice for diabetes mellitus, there 
has been development of obtaining the glucose variability 
in several situations. For clarifying the blood glucose 
fluctuation, continuous blood glucose monitoring (CGM) 
and self-monitoring of blood glucose (SMBG) have been 
used for years.  
Moreover, in the case of detail research level, 
there are some parameters which can be calculated. On the 
basis of SMBG and CGM, they include standard deviation  
(SD), M value, average daily risk range (ADRR), and mean 
amplitude of glycemic excursions (MAGE) and so on [19-
23] where they seemed to be beneficial as index of blood 
glucose fluctuation [23-25]. 
Taking most advantages of M value, 
pathophysiology of glucose variability has been 
investigated and clarified gradually [11, 13]. 
When comparing the average blood glucose level 
and the M value, the range of M value is broader and wider 
compared with that of value of blood glucose. That is one 
of the beneficial point of M value to utilize clinical research 
[26, 27]. It is because that M value expresses one 
numerical value, and that the level of M value means both 
average blood glucose and mean amplitude of glycemic 
excursions (MAGE) [28, 29].  
  In this study, various data concerning glucose 
variability and the responses of glucose and insulin against 
70g of carbohydrate were found. From diabetic point of 
view, we would discuss and speculate fundamental data 
and detail findings about several correlations. 
In the basic data of the subjects, the average value 
and the median value were almost equal in most items. On 
the other hand, there was a large difference between the 
average value and the median value only for the M value. 
The reason is probably due to the fact that the calculation 
formula for M value includes calculation to cube the 
difference value between measured glucose value and 
ideal glucose value. 
The change and response in IRI for 70 g 
carbohydrate increased from 12.4 to 30.6 μU/mL on 
median. In this study, we restrict cases with fasting IRI 
more than 10 μU/mL. Studies restricting the range of IRI 
values like this report have been rather rare. As a result, 
we would not derive some speculation, but the result will 
become the basic data for future research in this field. 
There was extremely high correlation coefficient 
between M value and average blood glucose. Its reason 
would be from the calculation method of M value, where 
average blood glucose is one of the several factors 
involved.  
According to the value of R2 of M value with each 
HOMA, it was 0.22 in HOMA-R and 0.58 in HOMA-β [30]. 
HOMA-R showed a significant positive correlation 
(p<0.01), and HOMA-β showed a significant negative 
correlation (p<0.01). Among them, the correlation 
coefficient was higher in the latter HOMA-β. The reason 
would be probably from the fact that M value includes 
mean blood glucose and MAGE with close relationship 
with insulin secretion, and that HOMA-β represents 
pancreas function, leading to higher correlation coefficient 
in the latter [31, 32].  
In current study, we investigated the correlation 
of biomarkers related to diabetes. The factors include 
HOMA-R and HOMA-β. Originally, HOMA was developed by 
Matthews [30]. By mathematical calculation, HOMA-R and 
HOMA-β are calculated from the balance between hepatic 
y = 3.5202x + 15.987 
R² = 0.6903 
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glucose output and insulin secretion from fasting levels of 
glucose and insulin [33].  
As the value of HOMA-R becomes higher, the 
insulin resistance becomes higher. Regarding the standard 
value of HOMA-R, it has been 1.73 or more with the 
presence of insulin resistance [34]. Subjects in this study 
were enrolled by the condition that fasting IRI was more 
than 10 μU/mL. Then, subjects seem to have insulin 
resistance. It is said that subjects indicating elevated 
HOMA-R are apt to suffer from myocardial infarction and 
cerebral infarction, regardless of diabetes. In other words, 
HOMA-R is not only for a judgment of insulin resistance 
but also for an indicator of cerebral cardiovascular events. 
Regarding HOMA-β, it is estimated to suppose the 
ability of secretion of insulin from the pancreas. By 
previous reports, elevated HOMA-R value and decreased 
HOMA-β value have been independently and consistently 
associated with an increased diabetes risk [34, 35]. 
Compared the obtained data of HOMA-R and HOMA-β, 
most subjects in this study did not show normal ranges, 
suggesting both of the existence of insulin resistance and 
decreased β-function.  
There were significant correlations between 
HOMA-β and both of Delta and AUC Ratio. The value of R2 
in Delta vs AUC were 0.19 vs 0.69, respectively. The latter 
showed higher correlation coefficient, suggesting that AUC 
calculation would be more adequate than Delta calculation 
in the research point of view. 
There have been several reports about clinical 
study of carbohydrate loading in breakfast. A trial of the 
international standard of test meal is found for the 
assessment of postprandial hyperglycemia [36]. This is 
called as Meal Tolerance Test (MTT) similar to GTT. There 
was another MTT which has carbohydrate 69g, similar to 
that of our investigation [37]. Among this report, glucose 
and IRI responses on 0 to 30 min were approximately 167 
mg/dL to 230 mg/dL, and 12μU/mL to 37 μU/mL, 
respectively. When we speculate and calculate detail data, 
Delta Ratio vs AUC Ratio of IGI seemed to be 0.39 vs 12.3, 
respectively. These values seemed to be compatible for 
our data in the cases with rather fair responses. 
As regard to the trials of Delta Ratio vs AUC Ratio 
of IGI, fundamental data have been accumulated at 
present. Current results would become the basal reference 
to develop this research in the future study. 
For the limits of current research, several aspects 
would be considered. Diabetes related factors can be 
involved by investigating the relationship among them. 
Probable biomarkers may include blood value and urinary 
excretion of C-peptide, basal data of renal and liver 
function test, the changes of triglyceride, HDL-C, LDL-C 
and so on. Furthermore, trial research about MTT would 
be developed in the future. 
 
4 Conclusion 
In summary, 32 patients with T2DM were 
investigated. Glucose variability and responses of glucose 
and IRI for carbohydrate loading were studied. At present, 
obtained data would become fundamental reference for 
the future study. Further development of research in this 
field will be expected.  
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